Loading organizations...
Loading organizations...
Quartet Medicine develops novel non-opioid therapeutics for chronic pain and inflammation. The company focuses on discovering and advancing small molecule medicines, offering alternative treatment pathways. Its scientific approach identifies new mechanisms of action, striving to provide safer, more effective solutions for complex pain conditions.
Co-founded by Kevin Pojasek and scientists from Boston Children's Hospital and EPFL in Switzerland, Quartet Medicine began operations around 2013. The company arose from a critical insight: an urgent need for innovative, non-addictive pain management strategies. Founders leveraged deep scientific expertise to translate advanced research into promising therapeutic candidates.
Quartet Medicine targets patients suffering from chronic pain and inflammatory conditions, aiming for effective relief without opioid-related risks. Its vision is to transform the treatment landscape for these debilitating diseases by introducing a new generation of non-addictive therapies. The company endeavors to improve patient quality of life through pioneering pharmaceutical development.
Quartet Medicine has raised $23.3M across 2 funding rounds.
Quartet Medicine has raised $23.3M in total across 2 funding rounds.
Quartet Medicine has raised $23.3M in total across 2 funding rounds.
Quartet Medicine's investors include John Creecy, Atlas Venture, Henry Skinner, Partners Innovation Fund, Pfizer.
# Quartet Medicine: Clarifying the Company Profile
Quartet Medicine is not a technology company—it is a biotechnology company focused on discovering and developing novel non-opioid medications for chronic pain and inflammation.[2][4] While the company employs technology platforms in its research, its primary business is pharmaceutical drug development rather than technology product creation.
Quartet Medicine operates as a private biotechnology firm dedicated to addressing the chronic pain and inflammation treatment landscape through innovative small molecule drug discovery.[2][4] The company's core mission centers on developing non-opioid therapeutics, positioning it within the broader effort to create alternatives to traditional opioid-based pain management.[4] Rather than building software or technology products for external users, Quartet Medicine serves the pharmaceutical and healthcare sectors by advancing its proprietary drug pipeline toward clinical and commercial viability.
The company targets a significant market need: chronic pain and inflammation represent major healthcare challenges, and the opioid crisis has created urgent demand for safer, non-addictive treatment alternatives. Quartet's approach focuses on a specific scientific pathway—small molecule modulators of the de novo BH4 synthesis pathway—as its mechanism for developing these next-generation therapeutics.[6]
Quartet Medicine participates in the larger movement toward precision pain management and opioid alternatives. The timing of its work aligns with increased healthcare system focus on reducing opioid dependence, regulatory pressure on opioid prescribing, and growing investment in non-addictive pain therapeutics. As healthcare providers and payers seek safer chronic pain solutions, companies developing novel mechanisms like Quartet's represent critical infrastructure for transforming treatment paradigms.
Quartet Medicine has raised $23.3M across 2 funding rounds. Most recently, it raised $6.3M Series A Extension in October 2015.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Oct 7, 2015 | $6.3M Series A Extension | John Creecy | |
| Oct 1, 2014 | $17.0M Series A | Atlas Venture | Henry Skinner, Partners Innovation Fund, Pfizer |